U.S. Markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.48-0.32 (-3.64%)
At close: 04:00PM EDT
8.54 +0.06 (+0.74%)
After hours: 06:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.80
Bid8.48 x 1400
Ask8.57 x 1400
Day's Range8.38 - 8.73
52 Week Range7.40 - 18.93
Avg. Volume430,952
Market Cap453.33M
Beta (5Y Monthly)1.08
PE Ratio (TTM)47.91
EPS (TTM)0.18
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • Simply Wall St.

    Here's Why We're Not Too Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Situation

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • GlobeNewswire

    Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

    STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company’s financial operations. “Ryan’s deep financial leadership experience will be instrument

  • Benzinga

    Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

    Cara Therapeutics Inc (NASDAQ: CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica (NP). Notalgia paresthetica (NP) is a nerve disorder that causes intense and sometimes painful itching in the back impacting quality of life. The data will be presented at the European Academy of Dermatology and Venereology (EADV) Congress. The presentation includes data from 125 patients with NP and moderate-to-severe pruri